All In Biotech

Drug Trial Radar · NCT04306224

A Study of IMC-002 in Subjects With Metastatic or Locally Advanced Solid Tumors and Relapsed or Refractory Lymphomas

A First-in-Human, Open-Label, Multiple-Ascending Dose Study to Investigate the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Clinical Activity of IMC-002 in Subjects With Metastatic or Locally Advanced Solid Tumors and Relapsed or Refractory Lymphomas

Last checked: Nov 20, 2026Latest source record: Sep 24, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Completed

Status

Completed

Enrollment

12

Actual

Start

Jun 5, 2020

Primary completion

Oct 7, 2022

Study completion Oct 7, 2022

Sponsor

Lead sponsor
ImmuneOncia Therapeutics Inc.Industry
Sponsor type
Industry
First posted
Mar 12, 2020

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1
Allocation
Not applicable (single group)
Model
Single group
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This is the first-in-human, Phase I, open-label, multiple-ascending dose study to investigate the safety, tolerability, PK, PharmDyn, and clinical activity of IMC-002 in subjects with metastatic or locally advanced solid tumors and relapsed or refractory lymphomas. Male or female subjects 18 years and older with metastatic or locally advanced solid tumors and relapsed or refractory lymphomas will be included in the study if they meet all the inclusion criteria and none of the exclusion criteria. The study will consist of 2 parts: Part 1: Dose Escalation Part 2: Expansion Cohorts

Conditions

  • Solid Tumor
  • Lymphoma

Interventions

  • IMC-002Biological

    IMC-002 blocks the interaction between CD47 and SIRPα.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Occurrence of dose-limiting toxicities (DLT)Time frame: For 28 days
  2. Incidence and severity of adverse events (AEs)Time frame: 2 years

Locations

4 sites in 2 countries. Site status is shown where the registry gives one.

  • Washington University School of Medicine - Siteman Cancer Center

    St Louis, Missouri

  • The University of Texas MD Anderson Cancer Center

    Houston, Texas

  • NEXT Oncology

    San Antonio, Texas

  • Seoul National University Hospital

    Seoul, South Korea

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.